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Raynaud’s phenomenon (RP) manifests as episodic vasospasm of the extremities (hands and 
feet) in response to cold exposure. RP can be primary (idiopathic) or secondary to underlying 
disease such as systemic sclerosis (SSc). Attacks of RP are often associated with digital colour 
changes reflecting local tissue perfusion and oxygenation. RP results in pain, numbness, 
impaired function and reduced quality of life [1, 2]. The obliterative vasculopathy of SSc can 
result in digital ulceration. Diagnostic delay of secondary RP remains a major unmet need. 
The average time between the onset of RP and the emergence of the first non-RP symptom 
in women with limited cutaneous SSc is >5 years [3]. This contributes to delay in diagnosis; 
with >25% of women not diagnosed with SSc for >10 years after RP symptoms first 
emerged[4]. 
Against this background, Scleroderma Raynaud’s UK (SRUK) developed a “Raynaud’s test” for 
their website (https://www.sruk.co.uk/raynauds/raynauds-test/). Visitors answer 5 
questions (derived from expert consensus RP classification criteria [5, 6]) to determine if RP 
was likely and whether medical assessment might be necessary (Table). 
No identifiable information is collected. Algorithms provide respondents with statements 
indicating “This is unlikely to be Raynaud’s” or that “You may have Raynaud’s”. All participants 
are encouraged to seek medical advice if they experience painful or frequent symptoms, or 
have other concerns. All participants answering “yes” to question 5 (irrespective of other 
responses) are given recommendations to be assessed by their primary care physician (Table).  
We examined anonymised data from 18840 respondents from 43 countries who completed 
the “Raynaud’s test” between 22/06/2017 and 21/06/2018. We have no information on who 
completed the test or how they acted on the information supplied in response to their 
answers. The figures are solely presented to provide some impression of the possible 
demographics of those completing the test. RP was deemed “unlikely” in 1138 (6%). The 
majority of respondents were informed they “may have Raynaud’s” (14140, 75%). The 
remaining 3562 respondents (19%) were also informed they may have Raynaud’s, but given 
additional advice to seek medical attention having reported the development of digital 
ischaemic lesions (yes to question 5). Accepting the inevitable selection bias accompanying 
positioning the test on the SRUK website, the considerable proportion of respondents 
reporting features that might represent SRP was of interest and it is hoped may have 
encouraged some respondents to seek medical attention when they had not previously done 
so.  
Utilisation of our Raynaud’s test highlights the large number of people visiting patient 
organisation websites for information and the potential of patient organisations to encourage 
involvement of people in their own healthcare. Our findings also highlight the global reach of 
“National” web-based patient organisations. The internet has provided the general public 
with a readily available tool for the self-investigation of new experiences/symptoms that 
might indicate the presence of disease. Carefully designed tools of this nature can positively 
influence health utilisation by providing reassurance to people interested to learn about RP 
and encouraging earlier medical assessment of people at risk of potentially life-threatening 
disease such as SSc. This type of interaction between healthcare professionals, patient 
organisations and the public is at the heart of important initiatives such as the EULAR ‘Don’t 
Delay, Connect Today!’ campaign, that is seeking to raise awareness around the importance 
of early diagnosis [7]. The diagnostic potential of mobile health technology is fast becoming 
an important tool for influencing patient referral processes and can be particularly valuable 
for people living in remote areas. We must, however, be alert to the dangers of diagnostic 
inaccuracy and incorporate appropriate safeguards that signpost people to seek healthcare 
assessment of intrusive or potentially serious symptomatology [8].  
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Table 1: The questions and responses comprising the online SRUK ‘Raynaud’s Test’ 
Questions (Q) comprising the Raynaud’s Test 
Question 1 Are your fingers sensitive to the cold?  
Question 2 Do your fingers change colour in response to temperature 
change or stressful situations? (white, blue, red and purple) 
Question 3 Do you get numbness or pain in the affected area when they 
change colour?  
Question 4 Do you feel stinging or throbbing when the affected area 
warms up? 
Question 5 Have you ever developed any sores/ulcers on your fingers or 
toes?  
Responses provided to visitors depending on their answers to questions 1-5 
No to Q1-5 OR  
Yes to Q1 but no to Q2-5 
This is unlikely to be Raynaud’s however if you 
experience painful or frequent symptoms, or are 
concerned, then it may be worthwhile visiting a GP 
You may be over sensitive to the cold and so to reduce your symptoms try to keep 
warm. Take a look at our information below to support you with keeping warm and 
avoiding smoking. If you would like to know more information about Raynaud’s then 
why not have a look at the further information below. Raynaud’s is a common 
condition affecting around 1 in 6 people. In people who have Raynaud's, the small 
blood vessels in the extremities are over-sensitive to changes in temperature or stress 
causing a Raynaud's attack Raynaud's symptoms generally affect the fingers and 
toes, but all extremities can be involved, including the ears. 
Yes to Q1, Yes to one of 
Q2-4, and No to Q5 
You may have Raynaud’s 
Raynaud’s is a common condition affecting around 1 in 6 people. In people who have 
Raynaud's, the small blood vessels in the extremities are over-sensitive to changes in 
temperature or stress. This causes a Raynaud's attack where the fingers change 
colour typically white, blue, or red. Raynaud's symptoms generally affect the fingers 
and toes, but all extremities can be involved, including the ears, nose, lips, tongue 
and nipples. If you are experiencing painful or frequent symptoms then it is worthwhile 
visiting your GP to discuss the situation, including management techniques and 
possible treatment options. 
Yes to Q5, irrespective of 
the answers provided to 
Q1-4 
You may have Raynaud’s 
Raynaud’s is a common condition affecting around 1 in 6 people. In people who have 
Raynaud's, the small blood vessels in the extremities are over-sensitive to changes in 
temperature or stress. This causes a Raynaud's attack where the fingers change 
colour typically white, blue, or red. Raynaud's symptoms generally affect the fingers 
and toes, but all extremities can be involved, including the ears, nose, lips, tongue 
and nipples. 
The majority of people with Raynaud’s symptoms have “Primary Raynaud’s 
phenomenon” which can be intrusive but should not cause any lasting damage to the 
fingers. Primary Raynaud’s often starts during adolescence. A minority of people 
experiencing Raynaud’s have an underlying health condition causing these 
symptoms. We use the term “Secondary Raynaud’s phenomenon” when this is the 
case. This can be more serious and we have tests available to help identify people 
who might have secondary Raynaud’s. 
If you have developed sores or ulcers on your fingers or toes then we would 
recommend an assessment at your GP surgery to rule out an underlying health 
problem. 
If you are experiencing painful or frequent symptoms then it is worthwhile visiting your 
GP to discuss the situation, including management techniques and possible treatment 
options. 
 
